Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.47 |
| ▸ | NOS2 | P35228 | 5/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CBLB | Q13191 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101542 | 1.00 | NOS3 (0.47) | NOS3NOS2NOS1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL31600990 | 0.98 | NOS3 (0.45) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL22838450 | 0.87 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL84401 | 0.82 | NOS3 (0.52) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL4322612 | 0.80 | NOS3 (0.50) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL514592 | 0.78 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL13391128 | 0.78 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL30953518 | 0.78 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL19077800 | 0.78 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL12204679 | 0.78 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458067-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR Therapeutics AG (CH) | 2019-03-27 | — | — | EP | claimed |
| EP-3458035-A1 | TREATMENT OF SKIN LESIONS | PIQUR Therapeutics AG (CH) | 2019-03-27 | — | — | EP | claimed |
| WO-2017198346-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2017-11-23 | — | — | WO | claimed |
| WO-2017198347-A1 | TREATMENT OF SKIN LESIONS | PIQUR THERAPEUTICS AG (CH) | 2017-11-23 | — | — | WO | claimed |
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2025-11-27 | — | — | US | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4538274-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2025-04-16 | — | — | EP | disclosed |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| US-20250034171-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2025-01-30 | — | — | US | disclosed |
| CN-119039290-A | P2X3 modulators | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-103153963-A | Cyclopropane compounds | EISAI R&D MAN CO LTD | 2013-06-12 | — | — | CN | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | STK11, STK35, STK10 | NOS3 3916/4885NOS2 4366/4885NOS1 3950/4885 |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | NOS3 1630/4885NOS2 1763/4885NOS1 1543/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | NOS3 340/4885NOS2 1357/4885NOS1 1639/4885 |
| US-20250034171-A1 | IMIDAZOPYRIDINE AMIDES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | TPMT, QDPR, BRD4 | NOS3 1709/4885NOS2 913/4885NOS1 1671/4885 |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | NOS3 3743/4885NOS2 4056/4885NOS1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.